Solid Biosciences’ muscular dystrophy gene therapy fails to hit the company’s own target, let alone a benchmark set by Sarepta.
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
The latest setback to Bristol-Myers Squibb’s first-line lung cancer plan sees it pull its US filing for Opdivo plus Yervoy.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.